Global Pharmacogenomics
Market Report
2024
Pharmacogenomics Market Report 2024 (Global Edition)
Delivery Includes:- Market Timeline 2019 till 2031, Market Size, Revenue/Volume Share, Forecast and CAGR, Competitor Analysis, Regional Analysis, Country Analysis, Segment Analysis, Market Trends, Drivers, Opportunities, Restraints, ESG Analysis, Porters Analysis, PESTEL Analysis, Market Attractiveness, Patent Analysis, Technological Trend, SWOT Analysis, COVID-19 Analysis, Consumer Behavior Analysis, etc.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
| Share your contact details to receive free updated sample copy/pages of the recently published edition of Pharmacogenomics Market Report 2024.
Global Pharmacogenomics Market Report 2024 Market Size Split by Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Others), by Application (Cardiova...
According to Cognitive Market Research, the Global Pharmacogenomics market will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.
North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031.
The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future.
Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million.
Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031.
The Pharmacogenomics market held the highest market revenue share in 2024.
| Base Year | 2023 |
| Historical Data Time Period | 2019-2023 |
| Forecast Period | 2024-2031 |
| Global Market Size | 121212 |
| Country Market Size | 121212 |
| North Americ Market Size | 121212 |
| Europe Market Size | 121212 |
| Asia Pacific Market Size | 121212 |
| South America Market Size | 121212 |
| Middle East and Africa Market Size | 121212 |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
| |
| Market Split by Technology |
|
| Market Split by Application |
|
| Market Split by End-User |
|
| List of Competitors |
|
| Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Pharmacogenomics industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Pharmacogenomics Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
Pharmacogenomics Market Report Description
Introduction of The Pharmacogenomics Market.
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications that can be prescribed based on a person’s genetic makeup. The field of pharmacogenomics is growing, and new approaches are under study in clinical trials. In the future, pharmacogenomics will be used to develop tailored drugs to treat a wide range of health problems, including cardiovascular disease, Alzheimer's disease, cancer, and asthma.
The growth in the market can be attributed to factors such as the growing number of chronic illnesses, the aging population, population increase, and the rising cost of cancer treatment. The introduction of three-dimensional (3D) genomics to study influences on gene expression and function, new product innovations with an emphasis on infectious diseases and gene editing, the development of a psychotropic pharmacogenomics test for informed decision-making, and the launch of a genome editing solution for deeper analysis of advanced therapies are among the major trends in the forecast period. Other trends include growing advancements in metagenomics and the focus on integrating artificial intelligence (AI) in genomics to analyze genetic data.
Market Dynamics of The Pharmacogenomics Market
Key Drivers for The Pharmacogenomics Market
- The increasing number of chronic diseases is driving the growth of the pharmacogenomics market.
The market for pharmacogenomics is mostly driven by the increased frequency of several illnesses, including cancer, neurological disorders, mental ailments, and cardiovascular diseases. The increasing prevalence of chronic disease conditions worldwide has led to a growing demand for more individualized and efficient treatment plans that address the various genetic variables impacting each patient's response to medicine.
For instance, in September 2023, according to the World Health Organization, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes.
Source:(https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases)
For instance, in June 2023, The NHS will conduct a pilot study to determine if it is feasible to provide pharmacogenomics testing for patients using statins, antidepressants, and proton pump inhibitors (PPIs). To ensure patients are taking the proper prescription and are not at risk for adverse effects when they start using a specific antidepressant, a fresh statin, or a proton pump inhibitor, the pilot will screen them.
Source:(https://pharmaceutical-journal.com/article/news/pharmacogenomic-testing-pilot-to-start-in-general-practice-from-june-2023)
The increasing number of chronic diseases require pharmacogenomics to offer a personalized approach for the treatment of chronic diseases Considering the individual genetic differences that affect a drug's reaction, hence driving the growth of the pharmacogenomics market.
- Increasing collaborations among research institutes drive the growth of the pharmacogenomics market
Increasing collaborations among research institutes drive the growth of the pharmacogenomics market by fostering knowledge exchange, resource sharing, and accelerated research progress. Through collaborative efforts, institutes can pool expertise, data, and infrastructure, facilitating more comprehensive studies and faster advancements in understanding genetic influences on drug response. This synergy enables the identification of new biomarkers, drug targets, and personalized treatment strategies, thereby enhancing the efficiency and efficacy of pharmacogenomics approaches in healthcare.
For instance, in August 2020, the University of California, San Francisco (UCSF), a health science university, expanded its pharmacogenomics efforts by launching a new collaboration with Tampa General Hospital and its pharmacy team that will allow clinicians to tailor medications based on a patient’s genetic makeup. Plans include developing clinical decision support tools in the electronic health record (EHR) to support clinicians in interpreting results and guiding treatment options in the presence of pharmacogenetic data.
source:(https://hscweb3.hsc.usf.edu/blog/2020/08/25/taneja-college-of-pharmacy-expands-personalized-medicine-in-collaboration-with-tampa-general-hospital/)
For instance, in March 2024 Western New England University College of Pharmacy and Health Sciences partnered with the American Pharmacogenomics Association to Enhance the Master of Science in Pharmacogenomics program. This collaboration marks a significant step forward in advancing education and research in the field of pharmacogenomics, where the study of how an individual's genetic makeup influences their response to medications is paramount.
Source:(https://wne.edu/news/2024/03/wne-apgxa-partnership.cfm)
Thus increasing collaboration with research institutes fosters technology innovations and significantly drives the growth of the pharmacogenomics market.
Restraint Factor for The Pharmacogenomics Market
-
The shortage of skilled healthcare professionals restrains the market growth of pharmacogenomics.
The shortage of skilled healthcare professionals capable of performing pharmacogenomics diagnostic tests and the lack of pharmacogenomics information integrated into electronic healthcare systems are anticipated to hinder market growth. Without enough trained personnel, the adoption and implementation of pharmacogenomics testing may be slow, limiting its accessibility and utilization. Additionally, the absence of pharmacogenomics data in electronic systems used by healthcare professionals could impede the seamless integration of genetic information into clinical decision-making processes, potentially leading to suboptimal treatment outcomes and slower market adoption. Addressing these challenges through education and technological integration is crucial for overcoming barriers to market growth in pharmacogenomics.
For instance, an article published in Frontiers, a publisher peer-reviewed open-access scientific journal, in September 2021, healthcare professionals lack adequate training and education in pharmacogenomics and they are concerned about the absence of evidence-based clinical guidelines
Source:(https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.724311/full)
Therefore, the market expansion is anticipated to be hampered by a shortage of qualified healthcare workers who can execute pharmacogenomics diagnostic tests and by a dearth of pharmacogenomics data in the electronic systems that healthcare professionals utilize.
Impact of Covid-19 on The Pharmacogenomics Market
The pharmacogenomics market was negatively affected by the COVID-19 pandemic because it forced the suspension of clinical studies, medication development, and diagnostic methods for illnesses other than COVID-19. According to a research paper released by PubMed in December 2021, the COVID-19 pandemic significantly decreased the number of procedures needed to detect cancer, which in turn led to a decrease in the number of new diagnoses throughout the United States. The number of new cancer diagnoses dropped from 13% to 23%, indicating that COVID-19 had a detrimental effect on this process. As the pandemic spread, COVID-19 had little beneficial effect on market expansion because of the rising need for genomics technology in the creation of COVID-19 diagnoses and treatments.
For instance, according to the Canadian Medical Association Journal findings, Researchers saw large reductions in the number of new diagnoses for some cancer types during the SOE period, with a drop of 43% (melanoma), 36% (colorectal and prostate) and 33% (breast). In the post-SOE phase, diagnoses increased by 9%, 8%, and 10% per month, respectively. In Ontario, there was a 34% drop in new cancer diagnoses in April 2020, and Manitoba had a 23% reduction in the same period. An estimated 15% reduction in Quebec occurred in the first year of the pandemic.
Source:(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260240/)
Opportunities for The Pharmacogenomics Market
- The growing adoption of precision medicine is a significant opportunity to drive the pharmacogenomics market growth.
Precision medicine, sometimes called personalized medicine, is a cutting-edge method of healthcare delivery that tailors medical treatment to each patient according to their unique genetic, genomic, and clinical features. As the industry moves towards more personalized medicine, pharmacogenomics could play a key role in keeping patients healthier longer and in getting them viable treatments for their unique genetic profile. This paradigm shift in healthcare has led to considerable advancements in the pharmacogenomics industry. Modern medicine is evolving as a result of the confluence of pharmacogenomics and personalized medicine, which has opened up new avenues for improving patient outcomes, reducing side events, and optimizing prescription management. The growing adoption of precision medicine is driving the pharmacogenomics industry by increasing therapeutic efficacy.
For instance, in October 2021, A partnership created to boost precision medicine research in Israel has chosen 11 multidisciplinary projects that will together get some NIS 32 million ($9.9 million) in funding to promote a variety of studies. These include the use of advanced algorithms and artificial intelligence for treating breast cancer and Crohn’s disease, genomic sequencing and analysis for the discovery of new disease genes, and treatments for rare disorders, and advanced machine learning image analysis to profile different cancers.
Source:(https://www.timesofisrael.com/11-israeli-projects-get-millions-in-funding-for-personalized-medicine-research/)
For instance, in May 2024 Recent patents, such as Scorpion Therapeutics Inc.’s inhibitors for cancer treatment and SCV-Spezial-Chemikalien-Vertrieb GmbH’s prostate cancer diagnostic labels, exemplify advancements in targeted therapies. As strategic investments and job growth highlight the importance of this field, the US continues to lead in the adoption and innovation of precision medicine.
Source:(https://www.pharmaceutical-technology.com/data-insights/precision-and-personalized-medicine-in-pharma/?cf-view)
Thus, the growing adoption of precision medicine for the treatment of infectious diseases including HIV/AIDS, TB, and cancer, as well as other disorders, is expected to drive the market over the forecast period.
We have various report editions of Pharmacogenomics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
Competitive Landscape: The Pharmacogenomics Market
Prominent industry players are making significant R&D investments to broaden their product offerings, hence contributing to the overall growth of the Pharmacogenomics market. To increase their market share, market players are also engaging in a range of calculated strategic actions. Notable developments in this regard include the introduction of new products, contracts, mergers and acquisitions, increased investment, and cooperation with other businesses.
• For instance, in January 2023, QIAGEN unveiled a strategic collaboration with Helix, a company specializing in population genomics to advance next-generation sequencing companion diagnostics in hereditary diseases. This partnership aims to facilitate combined offerings including accelerated patient recruitment, real-world evidence, and diagnostic solutions using NGS and PCR technologies
Source:(https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2023/QIAGEN-and-Helix-Launch-Exclusive-Partnership-to-Advance-Next-Generation-Sequencing-Companion-Diagnostics-in-Hereditary-Diseases/default.aspx)
Top Companies Market Share in Pharmacogenomics Industry: (In no particular order of Rank)
- Myriad Genetics
- Inc.
- 23andMe
- Inc.
- Pathway Genomics
- GeneTech
- Future Science Group
- Teva Pharmaceutical Industries Ltd.
- Assurex Health
- Inc.
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd.
- Merck & Co.
- Inc.
- Johnson & Johnson
- Abbott Laboratories
- Inc.
- Confidential Data
- Access The Paid Version
- Data Hidden
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Regional Analysis of The Pharmacogenomics Market
Which Region Will Dominate the Market in 2024?
According to Cognitive Research, the North American region dominated the Pharmacogenomics market and accounted for the highest revenue of XX% in 2024 and it is projected that it will grow at a CAGR of XX% in the future. North America region is the major thriving biotechnology and pharmaceutical sector, top academic institutions, cutting-edge research facilities, and a strong healthcare infrastructure. This kind of atmosphere encourages creativity and makes it easier for cutting-edge technologies—like pharmacogenomics—to be incorporated into clinical practice and research. Apart from the state-of-the-art healthcare infrastructure, the region's expansion is also propelled by favorable regulatory conditions, a high incidence of diseases, and a robust pharmaceutical sector. Therefore, it is anticipated that the increased emphasis on customized treatment would support the expansion of the U.S. market.
For instance, according to the American Cancer Society, in the U.S. the number of new cancer cases and cancer deaths were estimated to be 1.9 million and 609,360 respectively in 2022. Thus, the high incidence rates of cancer highlight the immense demand for pharmacogenomics testing and personalized treatment.
Source:(https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html)
For instance, the Blue Care Network introduced Blue Cross Personalized Medicine in Michigan in May 2022. This end-to-end pharmacogenomics precision medicine project looks at a list of recommended drugs for various forms of behavioral, oncological, and cardiovascular health conditions and then employs genetic testing to personalize prescription therapy for individual patients. In addition, the University of Chicago's 1200 Patients Project aimed to ascertain the feasibility and advantages of executing proactive pharmacogenomics testing of a set of genes.
Source:(https://mibluesperspectives.com/stories/community/blue-care-network-to-launch-blue-cross-personalized-medicine-michigans-first-end-to-end-pharmacogenomics-precision-medicine-program)
Which Region Is Expanding at The Fastest CAGR?
The Asia Pacific region's Pharmacogenomics market is expected to experience the fastest growth rate with a CAGR of XX% during the forecast period. Asia-Pacific is one of the global markets with the quickest rate of growth. As a result of improved healthcare and research in developing countries like Japan and India, diseases like cancer are becoming increasingly common. Cancer ranks among the leading causes of illness and patient death. Except for skin cancer, Asia-Pacific has one of the highest cancer prevalence rates in the world, per Globocan research. Furthermore, government expenditure and the growing ubiquity of genomic technologies, along with the rise of pharmaceutical companies, particularly biosimilars, have created significant opportunities in the sector.
For instance, in December 2022, MapMyGenome, a preventive genomics company, announced that it had launched MedicaMap, a pharmacogenomics solution that analyses an individual's response to medicines, based on genetic makeup.
Source:(https://diagnostics.mapmygenome.in/blog/mapmygenome-launches-pharmacogenomics-solution-medicamap)
The current report Scope analyzes Pharmacogenomics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
- North America (United States, Canada, Mexico)
- Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
- Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
- South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
- Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)
Pharmacogenomics Market Share (%) by Region (2019-2031)
The above graph is for illustrative purposes only.
To learn more about geographical trends request the free sample pages.
Get Free Sample
Pharmacogenomics Market Analysis
Global Pharmacogenomics Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Pharmacogenomics Industry growth. Pharmacogenomics market has been segmented with the help of its Technology, Application End-User, and others. Pharmacogenomics market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
Segment Performance in The Pharmacogenomics Market
Technology Segment Analysis
The DNA sequencing segment is estimated to hold the largest market share due to its speedy genetic information decoding. The ability of next-generation sequencing technology to read whole human genomes more swiftly and affordably than with earlier techniques has sped up scientific discoveries. This has facilitated the use of genetic data to influence treatment choices in the healthcare system. By matching patients with treatments that best fit their genetic profile thanks to DNA sequencing, doctors can reduce trial-and-error prescriptions and improve patient outcomes. It also makes it possible to track the development of the disease and find mutations that might make a treatment-resistant. Rapid DNA analyzers simplify pharmacogenomics testing to support precision prescribing across a range of therapeutic domains by automating sequencing operations for clinical laboratories. More pharmacogenomics applications might be supported by sequencing that is even quicker, less expensive, and simpler to interpret as a result of ongoing technical developments.
Pharmacogenomics Market Share (%) by Technology in 2019-2031
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Pharmacogenomics Industry. Request a Free Sample PDF!
Application Segment Analysis
The oncology segment is estimated to hold the largest market share due to the incidence of cancer. Pharmacogenomics takes into consideration the genetic differences of patients to maximize therapeutic effectiveness and decrease toxicity in cancer. The choice of treatments that target the underlying biological causes of cancer as well as biomarkers that indicate response or resistance is guided by genetic testing. Instead of randomized trials, it enables the matching of individuals with regimens best matched to their tumor characteristics. With this precise approach, non-responders can have their medicines swapped out early, improving results for subgroups. Identification of individuals who may need dosage reductions due to a high risk of drug-induced toxicity is another benefit of genomics analysis. Pharmacogenomics tracks genetic changes throughout illness progression and therapy, which helps overcome hurdles posed by tumor heterogeneity and evolution. It makes long-term monitoring easier to find resistance mutations that arise from targeted treatments. The realization of customized cancer care is contingent upon these capacities.
Pharmacogenomics Market Share (%) by Application in 2019-2031
2019
2023
2031
The above Graph is for representation purposes only. This chart does not depict actual Market share.
To learn more about market share request the free sample pages.
Get Free Sample
Pharmacogenomics End-User Segment Analysis
End-User Segment Analysis
The hospitals & clinics segment is estimated to hold the largest market share due to the growing clinical pharmacogenomics services they offer. To create platforms for precision medicine, hospitals are implementing genomic technologies such as microarrays and next-generation sequencing. This makes it possible to seamlessly integrate pharmacogenomics testing and consultation into clinical processes to drive patients' drug management. It aids in the early optimization of medication regimens. Hospitals that automate genetic profiling also give busy doctors easy access to board-certified pharmacogenomics specialists. By overcoming obstacles including multidisciplinary collaboration and challenging genetic data interpretation, this integrated testing and consulting paradigm improves the acceptance of pharmacogenomics. Increasing the range of clinical decision support tools will help medical practitioners apply test results even more. Hospital-based precision medicine services enhance pharmacogenomics applications and related economic results throughout the care continuum, with pharmacological consequences across therapeutic domains.
- Hospitals & Clinics
- Research Institutions and Academic Institutes
- Diagnostic Laboratories
- Others
Author's Detail
Manjiri KanhereSenior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over three years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies.
In her current role, Manjiri handles the market research related to Pharma and healthcare industry. Her passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.Manjiri remains an invaluable asset in the dynamic landscape of market research.
Author's Conclusion
With the help of the above study about the Pharmacogenomics market, it can be concluded that the market for pharmacogenomics worldwide is expected to develop significantly shortly. From the report, one can understand and infer the market dynamics, segmentations, status and trends, and key players in the market. It provides data regarding various topics such as market dimensions, prevailing trends, competitive landscape, and the outlook for prospective expansion. This allows the reader to understand and access reliable data about the market and industry.
Frequently Asked Questions
Please note, we have not disclose, all the sources consulted/referred during a market study due to confidentiality and paid service concern. However, rest assured that upon purchasing the service or paid report version, we will release the comprehensive list of sources along with the complete report and we also provide the data support where you can intract with the team of analysts who worked on the report.
Latest News about Pharmacogenomics Market
In February 2024, Golden Helix, Inc., a bioinformatics company, launched VSPGx, a pharmacogenomics solution for hospitals and testing labs.
Source:(https://synapse.patsnap.com/news-detail/b00f9d37-7e7e-395b-8b39-410596b34f76-golden-helix-is-launching-vspgx)
In May 2023, the University of California, San Francisco (UCSF), a health science university, announced that they had launched the first pharmacogenomics testing service in California, the health care delivered to patients at UCSF Health will be systematically informed by patient genomic data, ensuring that prescribed therapies are tailored to individuals’ unique biology
Source:(https://www.ucsf.edu/news/2023/05/425241/ucsf-first-california-provide-drug-gene-testing)
In December 2022, MapMyGenome, a preventive genomics company, announced that it had launched MedicaMap, a pharmacogenomics solution that analyses an individual's response to medicines, based on genetic makeup.
Source:(https://diagnostics.mapmygenome.in/blog/mapmygenome-launches-pharmacogenomics-solution-medicamap)
Sources from Pharma & Healthcare Industry
- https://en.wikipedia.org/wiki/American_Society_for_Pharmacy_Law
- https://en.wikipedia.org/wiki/American_Society_of_Consultant_Pharmacists
- https://en.wikipedia.org/wiki/American_Society_of_Health-System_Pharmacists
- https://www.apsm-uk.com/
- https://en.wikipedia.org/wiki/Australasian_College_of_Pharmacy
- https://en.wikipedia.org/wiki/American_Association_of_Colleges_of_Pharmacy
- https://en.wikipedia.org/wiki/American_College_of_Clinical_Pharmacy
- https://en.wikipedia.org/wiki/American_Pharmacists_Association
- https://www.bio.org/
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Association
- https://en.wikipedia.org/wiki/Canadian_Society_of_Hospital_Pharmacists
- https://en.wikipedia.org/wiki/Chinese_Pharmaceutical_Association
- https://en.wikipedia.org/wiki/American_Association_of_Psychiatric_Pharmacists
- https://en.wikipedia.org/wiki/Danish_Association_of_Pharmaconomists
- https://en.wikipedia.org/wiki/EPhEU
- https://www.fda.gov/
- https://www.gmc-uk.org/
- https://www.ifpma.org/
- https://www.fip.org/
- https://en.wikipedia.org/wiki/International_Pharmaceutical_Students%27_Federation
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://en.wikipedia.org/wiki/National_Pharmacy_Association
- https://en.wikipedia.org/wiki/Norwegian_Pharmacy_Association
- https://en.wikipedia.org/wiki/Canadian_Pharmacists_Journal#History
- https://en.wikipedia.org/wiki/Pakistan_Pharmacists_Association
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Mauritius
- https://en.wikipedia.org/wiki/Pharmaceutical_Group_of_the_European_Union
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Australia
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_New_Zealand
- https://en.wikipedia.org/wiki/Pharmaceutical_Society_of_Northern_Ireland
- https://en.wikipedia.org/wiki/Professional_Compounding_Centers_of_America
- https://en.wikipedia.org/wiki/Royal_Pharmaceutical_Society
- https://www.aaps.org/home
- https://www.bioindustry.org/
- https://www.controlledreleasesociety.org/
- https://www.efpia.eu/
- https://www.epemed.org/online/www/content/ENG/index.html
- https://icr-global.org/
- https://ispe.org/
- https://en.wikipedia.org/wiki/Pharmaceutical_Association_of_Israel
- https://www.phrma.org/
- https://en.wikipedia.org/wiki/The_Pharmacy_Guild_of_Australia
- https://en.wikipedia.org/wiki/The_Society_of_Hospital_Pharmacists_of_Australia
- https://en.wikipedia.org/wiki/Healthcare_industry
- https://www.pharma-iq.com/business-development/articles/top-50-pharmaceutical-blogs-and-publications
- https://www.pharmatimes.com/news
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967517/
- https://www.cbo.gov/publication/57126
- http://: https://www.who.int/tools/atc-ddd-toolkit/data
- https://www.oecd.org/els/health-systems/health-data.htm
- https://www.bls.gov/ooh/healthcare/home.htm
- https://data.worldbank.org/topic/8
- https://www.statnews.com/about/
- https://www.health.pa.gov/topics/HealthStatistics/Pages/health-statistics.aspx
- https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Healthcare_expenditure_statistics
- https://www.cdc.gov/nchs/index.htm
- https://www.aha.org/statistics/fast-facts-us-hospitals
- https://www.census.gov/library/publications/2021/demo/p60-274.html
- https://www.adb.org/what-we-do/sectors/health/main
Pharmacogenomics Market Report Table of Content
Disclaimer:
- This is just a redacted sample pages of the actual deliverable report and only for representative purposes
- Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
- The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
- Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
- If applicable; On Request Volume Data will also be provided (at an Additional Cost).
| Technology | DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Others |
| Application | Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Pain Management, Others |
| End-User | Hospitals & Clinics, Research Institutions and Academic Institutes, Diagnostic Laboratories, Others |
| List of Competitors | Myriad Genetics, Inc., 23andMe, Inc., Pathway Genomics, GeneTech, Future Science Group, Teva Pharmaceutical Industries Ltd., Assurex Health, Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., Merck & Co., Inc., Johnson & Johnson, Abbott Laboratories, Inc. |
This chapter will help you gain GLOBAL Market Analysis of Pharmacogenomics. Further deep in this chapter, you will be able to review Global Pharmacogenomics Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
-
1.1 Global Pharmacogenomics Market Size, Trend Analysis 2019 - 2031
-
1.2 Global Pharmacogenomics Market Size By Regions 2019 - 2031
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
-
1.2.1 Global Pharmacogenomics Revenue Market Size By Region
-
-
1.3 Global Pharmacogenomics Market Size By Technology 2019 -2031
-
1.3.1 DNA Sequencing Market Size
-
1.3.2 Microarray Market Size
-
1.3.3 Polymerase Chain Reaction Market Size
-
1.3.4 Electrophoresis Market Size
-
1.3.5 Mass Spectrometry Market Size
-
1.3.6 Others Market Size
-
-
1.4 Global Pharmacogenomics Market Size By Application 2019 -2031
-
1.4.1 Cardiovascular Diseases Market Size
-
1.4.2 Infectious Diseases Market Size
-
1.4.3 Oncology Market Size
-
1.4.4 Neurological Diseases Market Size
-
1.4.5 Pain Management Market Size
-
1.4.6 Others Market Size
-
-
1.5 Global Pharmacogenomics Market Size By End-User 2019 -2031
-
1.5.1 Hospitals & Clinics Market Size
-
1.5.2 Research Institutions and Academic Institutes Market Size
-
1.5.3 Diagnostic Laboratories Market Size
-
1.5.4 Others Market Size
-
-
1.6 Global Level Competitor Analysis (Subject to Data Availability (Private Players))
-
1.7 Executive Summary Global Market (2019 vs 2024 vs 2031)
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
-
1.7.1 Regional Market Revenue Summary 2019 vs 2024 vs 2031
-
1.7.2 Global Market Revenue Split By Technology
-
1.7.3 Global Market Revenue Split By Application
-
1.7.4 Global Market Revenue Split By End-User
-
1.7.5 Global Market Dynamics, Trends, Drivers, Restraints, Opportunities
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
-
Chapter 2 North America Market Analysis
-
2.1 North America Pharmacogenomics Market Size 2019 - 2031
-
2.1.1 North America Pharmacogenomics Market Size By Country 2019 - 2031
-
2.1.2 North America Pharmacogenomics Market Size by Technology 2019 -2031
-
2.1.2.1 North America DNA Sequencing Market Size
-
2.1.2.2 North America Microarray Market Size
-
2.1.2.3 North America Polymerase Chain Reaction Market Size
-
2.1.2.4 North America Electrophoresis Market Size
-
2.1.2.5 North America Mass Spectrometry Market Size
-
2.1.2.6 North America Others Market Size
-
-
2.1.3 North America Pharmacogenomics Market Size by Application 2019 -2031
-
2.1.3.1 North America Cardiovascular Diseases Market Size
-
2.1.3.2 North America Infectious Diseases Market Size
-
2.1.3.3 North America Oncology Market Size
-
2.1.3.4 North America Neurological Diseases Market Size
-
2.1.3.5 North America Pain Management Market Size
-
2.1.3.6 North America Others Market Size
-
-
2.1.4 North America Pharmacogenomics Market Size by End-User 2019 -2031
-
2.1.4.1 North America Hospitals & Clinics Market Size
-
2.1.4.2 North America Research Institutions and Academic Institutes Market Size
-
2.1.4.3 North America Diagnostic Laboratories Market Size
-
2.1.4.4 North America Others Market Size
-
-
Chapter 3 Europe Market Analysis
-
3.1 Europe Pharmacogenomics Market Size 2019 - 2031
-
3.1.1 Europe Pharmacogenomics Market Size By Country 2019 - 2031
-
3.1.2 Europe Pharmacogenomics Market Size by Technology 2019 -2031
-
3.1.2.1 Europe DNA Sequencing Market Size
-
3.1.2.2 Europe Microarray Market Size
-
3.1.2.3 Europe Polymerase Chain Reaction Market Size
-
3.1.2.4 Europe Electrophoresis Market Size
-
3.1.2.5 Europe Mass Spectrometry Market Size
-
3.1.2.6 Europe Others Market Size
-
-
3.1.3 Europe Pharmacogenomics Market Size by Application 2019 -2031
-
3.1.3.1 Europe Cardiovascular Diseases Market Size
-
3.1.3.2 Europe Infectious Diseases Market Size
-
3.1.3.3 Europe Oncology Market Size
-
3.1.3.4 Europe Neurological Diseases Market Size
-
3.1.3.5 Europe Pain Management Market Size
-
3.1.3.6 Europe Others Market Size
-
-
3.1.4 Europe Pharmacogenomics Market Size by End-User 2019 -2031
-
3.1.4.1 Europe Hospitals & Clinics Market Size
-
3.1.4.2 Europe Research Institutions and Academic Institutes Market Size
-
3.1.4.3 Europe Diagnostic Laboratories Market Size
-
3.1.4.4 Europe Others Market Size
-
-
Chapter 4 Asia Pacific Market Analysis
-
4.1 Asia Pacific Pharmacogenomics Market Size 2019 - 2031
-
4.1.1 Asia Pacific Pharmacogenomics Market Size By Country 2019 - 2031
-
4.1.2 Asia Pacific Pharmacogenomics Market Size by Technology 2019 -2031
-
4.1.2.1 Asia Pacific DNA Sequencing Market Size
-
4.1.2.2 Asia Pacific Microarray Market Size
-
4.1.2.3 Asia Pacific Polymerase Chain Reaction Market Size
-
4.1.2.4 Asia Pacific Electrophoresis Market Size
-
4.1.2.5 Asia Pacific Mass Spectrometry Market Size
-
4.1.2.6 Asia Pacific Others Market Size
-
-
4.1.3 Asia Pacific Pharmacogenomics Market Size by Application 2019 -2031
-
4.1.3.1 Asia Pacific Cardiovascular Diseases Market Size
-
4.1.3.2 Asia Pacific Infectious Diseases Market Size
-
4.1.3.3 Asia Pacific Oncology Market Size
-
4.1.3.4 Asia Pacific Neurological Diseases Market Size
-
4.1.3.5 Asia Pacific Pain Management Market Size
-
4.1.3.6 Asia Pacific Others Market Size
-
-
4.1.4 Asia Pacific Pharmacogenomics Market Size by End-User 2019 -2031
-
4.1.4.1 Asia Pacific Hospitals & Clinics Market Size
-
4.1.4.2 Asia Pacific Research Institutions and Academic Institutes Market Size
-
4.1.4.3 Asia Pacific Diagnostic Laboratories Market Size
-
4.1.4.4 Asia Pacific Others Market Size
-
-
Chapter 5 South America Market Analysis
-
5.1 South America Pharmacogenomics Market Size 2019 - 2031
-
5.1.1 South America Pharmacogenomics Market Size By Country 2019 - 2031
-
5.1.2 South America Pharmacogenomics Market Size by Technology 2019 -2031
-
5.1.2.1 South America DNA Sequencing Market Size
-
5.1.2.2 South America Microarray Market Size
-
5.1.2.3 South America Polymerase Chain Reaction Market Size
-
5.1.2.4 South America Electrophoresis Market Size
-
5.1.2.5 South America Mass Spectrometry Market Size
-
5.1.2.6 South America Others Market Size
-
-
5.1.3 South America Pharmacogenomics Market Size by Application 2019 -2031
-
5.1.3.1 South America Cardiovascular Diseases Market Size
-
5.1.3.2 South America Infectious Diseases Market Size
-
5.1.3.3 South America Oncology Market Size
-
5.1.3.4 South America Neurological Diseases Market Size
-
5.1.3.5 South America Pain Management Market Size
-
5.1.3.6 South America Others Market Size
-
-
5.1.4 South America Pharmacogenomics Market Size by End-User 2019 -2031
-
5.1.4.1 South America Hospitals & Clinics Market Size
-
5.1.4.2 South America Research Institutions and Academic Institutes Market Size
-
5.1.4.3 South America Diagnostic Laboratories Market Size
-
5.1.4.4 South America Others Market Size
-
-
Chapter 6 Middle East and Africa Market Analysis
-
6.1 Middle East and Africa Pharmacogenomics Market Size 2019 - 2031
-
6.1.1 Middle East and Africa Pharmacogenomics Market Size By Country 2019 - 2031
-
6.1.2 Middle East and Africa Pharmacogenomics Market Size by Technology 2019 -2031
-
6.1.2.1 Middle East and Africa DNA Sequencing Market Size
-
6.1.2.2 Middle East and Africa Microarray Market Size
-
6.1.2.3 Middle East and Africa Polymerase Chain Reaction Market Size
-
6.1.2.4 Middle East and Africa Electrophoresis Market Size
-
6.1.2.5 Middle East and Africa Mass Spectrometry Market Size
-
6.1.2.6 Middle East and Africa Others Market Size
-
-
6.1.3 Middle East and Africa Pharmacogenomics Market Size by Application 2019 -2031
-
6.1.3.1 middle_east_and_africa_title} Cardiovascular Diseases Market Size
-
6.1.3.2 middle_east_and_africa_title} Infectious Diseases Market Size
-
6.1.3.3 middle_east_and_africa_title} Oncology Market Size
-
6.1.3.4 middle_east_and_africa_title} Neurological Diseases Market Size
-
6.1.3.5 middle_east_and_africa_title} Pain Management Market Size
-
6.1.3.6 middle_east_and_africa_title} Others Market Size
-
-
6.1.4 Middle East and Africa Pharmacogenomics Market Size by End-User 2019 -2031
-
6.1.4.1 Middle East and Africa Hospitals & Clinics Market Size
-
6.1.4.2 Middle East and Africa Research Institutions and Academic Institutes Market Size
-
6.1.4.3 Middle East and Africa Diagnostic Laboratories Market Size
-
6.1.4.4 Middle East and Africa Others Market Size
-
-
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis (Only Available with Corporate User License)
-
7.1 Country 1 Market Analysis
-
7.1.1 Country 1Pharmacogenomics Market Size by Technology 2019 -2031
-
7.1.2 Country 1Pharmacogenomics Market Size by Application 2019 -2031
-
7.1.3 Country 1Pharmacogenomics Market Size by End-User 2019 -2031
-
-
7.2 Country 2 Market Analysis
-
7.2.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.3 Country 3 Market Analysis
-
7.3.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.4 Country 4 Market Analysis
-
7.4.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.5 Country 5 Market Analysis
-
7.5.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.6 Country 6 Market Analysis
-
7.6.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.7 Country 7 Market Analysis
-
7.7.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.8 Country 8 Market Analysis
-
7.8.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.9 Country 9 Market Analysis
-
7.9.1 Segmentation Analysis will be provided as shown for Country 1
-
-
7.10 Country 10 Market Analysis
-
7.10.1 Segmentation Analysis will be provided as shown for Country 1
-
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
-
8.1 Top Competitors Analysis
-
8.1.1 Top Players Ranking 2022
-
8.1.2 Global Pharmacogenomics Market Revenue and Share by Manufacturers (2019-2023)
(Subject to Data Availability (Private Players))
-
8.1.3 Industry Mergers and Acquisition Analysis
-
8.1.4 New Product Launch Analysis
-
-
8.2 Company Profile (Data Subject to Availability)
-
8.2.1 Myriad Genetics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.1.2 Business Overview
-
8.2.1.3 Financials (Subject to data availability)
-
8.2.1.4 Product Types Specification
-
8.2.1.5 Business Strategy
-
8.2.1.6 S.W.O.TAnalysis
-
-
8.2.2 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.2.2 Business Overview
-
8.2.2.3 Financials (Subject to data availability)
-
8.2.2.4 Product Types Specification
-
8.2.2.5 Business Strategy
-
8.2.2.6 S.W.O.TAnalysis
-
-
8.2.3 23andMe
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.3.2 Business Overview
-
8.2.3.3 Financials (Subject to data availability)
-
8.2.3.4 Product Types Specification
-
8.2.3.5 Business Strategy
-
8.2.3.6 S.W.O.TAnalysis
-
-
8.2.4 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.4.2 Business Overview
-
8.2.4.3 Financials (Subject to data availability)
-
8.2.4.4 Product Types Specification
-
8.2.4.5 Business Strategy
-
8.2.4.6 S.W.O.TAnalysis
-
-
8.2.5 Pathway Genomics
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.5.2 Business Overview
-
8.2.5.3 Financials (Subject to data availability)
-
8.2.5.4 Product Types Specification
-
8.2.5.5 Business Strategy
-
8.2.5.6 S.W.O.TAnalysis
-
-
8.2.6 GeneTech
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.6.2 Business Overview
-
8.2.6.3 Financials (Subject to data availability)
-
8.2.6.4 Product Types Specification
-
8.2.6.5 Business Strategy
-
8.2.6.6 S.W.O.TAnalysis
-
-
8.2.7 Future Science Group
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.7.2 Business Overview
-
8.2.7.3 Financials (Subject to data availability)
-
8.2.7.4 Product Types Specification
-
8.2.7.5 Business Strategy
-
8.2.7.6 S.W.O.TAnalysis
-
-
8.2.8 Teva Pharmaceutical Industries Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.8.2 Business Overview
-
8.2.8.3 Financials (Subject to data availability)
-
8.2.8.4 Product Types Specification
-
8.2.8.5 Business Strategy
-
8.2.8.6 S.W.O.TAnalysis
-
-
8.2.9 Assurex Health
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.9.2 Business Overview
-
8.2.9.3 Financials (Subject to data availability)
-
8.2.9.4 Product Types Specification
-
8.2.9.5 Business Strategy
-
8.2.9.6 S.W.O.TAnalysis
-
-
8.2.10 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.10.2 Business Overview
-
8.2.10.3 Financials (Subject to data availability)
-
8.2.10.4 Product Types Specification
-
8.2.10.5 Business Strategy
-
8.2.10.6 S.W.O.TAnalysis
-
-
8.2.11 Bristol-Myers Squibb Company
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.11.2 Business Overview
-
8.2.11.3 Financials (Subject to data availability)
-
8.2.11.4 Product Types Specification
-
8.2.11.5 Business Strategy
-
8.2.11.6 S.W.O.TAnalysis
-
-
8.2.12 Hoffmann-La Roche Ltd.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.12.2 Business Overview
-
8.2.12.3 Financials (Subject to data availability)
-
8.2.12.4 Product Types Specification
-
8.2.12.5 Business Strategy
-
8.2.12.6 S.W.O.TAnalysis
-
-
8.2.13 Merck & Co.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.13.2 Business Overview
-
8.2.13.3 Financials (Subject to data availability)
-
8.2.13.4 Product Types Specification
-
8.2.13.5 Business Strategy
-
8.2.13.6 S.W.O.TAnalysis
-
-
8.2.14 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.14.2 Business Overview
-
8.2.14.3 Financials (Subject to data availability)
-
8.2.14.4 Product Types Specification
-
8.2.14.5 Business Strategy
-
8.2.14.6 S.W.O.TAnalysis
-
-
8.2.15 Johnson & Johnson
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.15.2 Business Overview
-
8.2.15.3 Financials (Subject to data availability)
-
8.2.15.4 Product Types Specification
-
8.2.15.5 Business Strategy
-
8.2.15.6 S.W.O.TAnalysis
-
-
8.2.16 Abbott Laboratories
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.16.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.16.2 Business Overview
-
8.2.16.3 Financials (Subject to data availability)
-
8.2.16.4 Product Types Specification
-
8.2.16.5 Business Strategy
-
8.2.16.6 S.W.O.TAnalysis
-
-
8.2.17 Inc.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
-
8.2.17.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
-
8.2.17.2 Business Overview
-
8.2.17.3 Financials (Subject to data availability)
-
8.2.17.4 Product Types Specification
-
8.2.17.5 Business Strategy
-
8.2.17.6 S.W.O.TAnalysis
-
-
Chapter 9 Qualitative Analysis (Subject to Data Availability)
-
9.1 Market Drivers
-
9.2 Market Trends
-
9.3 Market Restraints
-
9.4 Market Opportunity
-
9.5 Product Life Cycle (Subject to Data Availability)
-
9.6 Industrial Chain Analysis (Subject to Data Availability)
-
9.6.1 Industry Chain Analysis
-
9.6.2 Manufacturing Cost Analysis
-
9.6.3 Consumer Preference Analysis
-
9.6.4 Supply Side Analysis
-
9.6.4.1 Raw Material Analysis
-
9.6.4.2 Raw Material Procurement Analysis
-
9.6.4.3 Raw Material Price Trend Analysis
-
-
-
9.7 Market Attractiveness Analysis
-
9.8 PESTEL Analysis
-
9.9 Porter’s Five Forces Analysis
-
9.10 Patent Analysis (Subject to Data Availability)
-
9.11 ESG Analysis
-
9.12 Technological Road Map
Segmentation Technology Analysis 2019 -2031, will provide market size split by Technology. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Technology Analysis 2019 -2031
-
10.1 DNA Sequencing
-
10.1.1 Global Pharmacogenomics Revenue Market Size and Share by DNA Sequencing 2019 -2031
-
-
10.2 Microarray
-
10.2.1 Global Pharmacogenomics Revenue Market Size and Share by Microarray 2019 -2031
-
-
10.3 Polymerase Chain Reaction
-
10.3.1 Global Pharmacogenomics Revenue Market Size and Share by Polymerase Chain Reaction 2019 -2031
-
-
10.4 Electrophoresis
-
10.4.1 Global Pharmacogenomics Revenue Market Size and Share by Electrophoresis 2019 -2031
-
-
10.5 Mass Spectrometry
-
10.5.1 Global Pharmacogenomics Revenue Market Size and Share by Mass Spectrometry 2019 -2031
-
-
10.6 Others
-
10.6.1 Global Pharmacogenomics Revenue Market Size and Share by Others 2019 -2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Application Analysis 2019 -2031
-
11.1 Cardiovascular Diseases
-
11.1.1 Global Pharmacogenomics Revenue Market Size and Share by Cardiovascular Diseases 2019 - 2031
-
-
11.2 Infectious Diseases
-
11.2.1 Global Pharmacogenomics Revenue Market Size and Share by Infectious Diseases 2019 - 2031
-
-
11.3 Oncology
-
11.3.1 Global Pharmacogenomics Revenue Market Size and Share by Oncology 2019 - 2031
-
-
11.4 Neurological Diseases
-
11.4.1 Global Pharmacogenomics Revenue Market Size and Share by Neurological Diseases 2019 - 2031
-
-
11.5 Pain Management
-
11.5.1 Global Pharmacogenomics Revenue Market Size and Share by Pain Management 2019 - 2031
-
-
11.6 Others
-
11.6.1 Global Pharmacogenomics Revenue Market Size and Share by Others 2019 - 2031
-
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by End-User Analysis 2019 -2031
-
12.1 Hospitals & Clinics
-
12.1.1 Global Pharmacogenomics Revenue Market Size and Share by Hospitals & Clinics 2019 -2031
-
-
12.2 Research Institutions and Academic Institutes
-
12.2.1 Global Pharmacogenomics Revenue Market Size and Share by Research Institutions and Academic Institutes 2019 -2031
-
-
12.3 Diagnostic Laboratories
-
12.3.1 Global Pharmacogenomics Revenue Market Size and Share by Diagnostic Laboratories 2019 -2031
-
-
12.4 Others
-
12.4.1 Global Pharmacogenomics Revenue Market Size and Share by Others 2019 -2031
-
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Pharmacogenomics market
Chapter 13 Research Findings
-
13.1 Key Takeaways
-
13.2 Analyst Point of View
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
-
13.3 Assumptions and Acronyms
Sample Format of Deliverables
The Tables, Graphs/Charts are only for representative purposes and do not depict actual statistics. Purchase full Report access to actual data.
Qualitative Analysis
Research Methodology Implemented by Manjiri Kanhere and Team
- 1.1 Pharmacogenomics Market Report 2024 Research Methodology
- 1.2 Systematic Research Approach
- 1.2.1 Primary Research for Pharmacogenomics Market
- 1.2.1.1 Key Data from Primary
- 1.2.1.2 Primary Interviews with Experts
- 1.2.1.3 Key Industry Insights
- 1.2.1.4 Questionnaire for Pharmacogenomics Market
- 1.2.1.5 Breakdown of Primaries
- 1.2.2 Secondary Research for Pharmacogenomics Market
- 1.2.2.1 Key Data from Secondary
- 1.2.2.2 Paid Sources
- 1.2.2.3 Public Sources
- 1.3 Market Size Estimation for Pharmacogenomics Market
- 1.3.1 Top-Down Approach
- 1.3.1.1 Analyzing Market Size by Top-Down Approach (Supply Side)
- 1.3.2 Bottom-UP Approach
- 1.3.2.1 Analyzing Market Size by Bottom-Up Approach (Demand Side)
- 1.3.1 Top-Down Approach
- 1.4 Market Breakdown and Data Triangulation
- 1.5 Research Assumptions for Pharmacogenomics Market
Key Questions Answered By Pharmacogenomics Market Report 2024
| Why DNA Sequencing have a significant impact on Pharmacogenomics market? |
| What are the key factors affecting the DNA Sequencing and Microarray of Pharmacogenomics Market? |
| What is the CAGR/Growth Rate of Cardiovascular Diseases during the forecast period? |
| By type, which segment accounted for largest share of the global Pharmacogenomics Market? |
| Which region is expected to dominate the global Pharmacogenomics Market within the forecast period? |
| Segmentation Level Customization |
|
| Global level Data Customization |
|
| Region level Data Customization |
|
| Country level Data Customization |
|
| Company Level |
|
| Additional Data Analysis |
|
| Additional Qualitative Data |
|
| Additional Quantitative Data |
|
| Service Level Customization |
|
Report Format Alteration |
|
